The BCL2L12 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1, in which the BCL2L12 gene has been disrupted to generate a loss-of-function model. This polyclonal knockout product captures heterogeneous editing outcomes, enabling the study of BCL2L12 in a diverse cancer cell context. CRISPR/Cas9-mediated gene disruption abolishes endogenous BCL2L12, providing a tool to dissect its complex roles in apoptosis regulation.
The host cell line SK-HEP-1 was established from ascitic fluid of a patient with liver adenocarcinoma and exhibits a mixed epithelial/mesenchymal phenotype, making it a valuable model for hepatic adenocarcinoma, particularly for investigating epithelial-mesenchymal transition (EMT) and cancer cell migration. SK-HEP-1 cells are widely used in studies of cancer cell motility, endothelial biology, and tumor microenvironment interactions, offering a platform to explore how apoptotic regulators influence metastatic behaviors.
BCL2L12 generates pro-apoptotic and anti-apoptotic isoforms via alternative splicing, modulating intrinsic apoptosis primarily at the mitochondrial level. The protein interacts with key BCL-2 family members??including BCL-2, BCL-XL, BAX, BAK, BAD, and BIM??to regulate mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release. Downstream, cytochrome c activates APAF1-mediated Caspase-9, leading to executioner Caspase-3 activation and apoptosis. Upstream, BCL2L12 is transcriptionally regulated by p53, NF-??B, and STAT3 in response to DNA damage and cellular stress, thereby positioning it as a critical node integrating survival and death signals.
In the context of SK-HEP-1 cells, disruption of BCL2L12 offers a physiologically relevant model to investigate the gene??s putative tumor suppressor role in liver adenocarcinoma. The mixed epithelial/mesenchymal background of these cells allows researchers to evaluate how loss of BCL2L12 impacts both apoptosis sensitivity and migration capacity, potentially revealing dual functions in tumor progression. Given that BCL2L12 is implicated in hepatocellular carcinoma, colorectal, breast, glioma, and gastric cancers, this knockout model provides a versatile platform to assess BCL2L12-dependent pathways and therapeutic vulnerabilities in a hepatic cancer setting.
This polyclonal knockout product is well-suited for a range of experimental applications, including functional dissection of BCL2L12??s role in apoptosis, drug sensitivity screening, and mechanistic studies of alternative splicing. Key assays include Western blotting and RT-qPCR for isoform analysis, flow cytometry with Annexin V/PI, MTT and Caspase-3/7 activity assays, mitochondrial membrane potential measurements, and wound healing assays for migration. RNA-seq enables transcriptome-wide profiling. For further information or to discuss custom applications, please contact Ascent Research.
